News und Analysen

UnitedHealth Group (NYSE: UNH) is the largest private health insurance company in the U.S., with more than 400,000 employees. It pulled in $324.2 billion in revenue last year, making it the largest

Amid last year's difficult market, you may not have put all of your investable money to work -- in which case, you might have cash sitting on the sidelines. This would be the perfect time to deploy

Shares of Novavax (NASDAQ: NVAX) were up more than 24% as of 12:08 p.m. ET on Monday after the biotech company said Friday that Canada will pay $349.6 million for unused COVID-19 shots from the

At any given time, the market may not be appropriately valuing a stock based on the fundamentals of its underlying business. This is because market participants aren't always completely rational

A good measure of a truly great business is that it outperforms the broader market over the long haul. This is because over the long term total returns tend to be more closely aligned with

Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the

Some decisions are hard. Others, however, are so easy that they require much less thought.

Three Motley Fool contributors believe they've found stocks to buy that definitely fall into the latter

Shares of transplant diagnostics company CareDx (NASDAQ: CDNA) were up more than 20% as of 12:20 p.m. ET on Friday after a decision by the Centers for Medicare & Medicaid Services (CMS) that could

Turning an initial capital of, say, $1000 into double that in half a decade amounts to a compound annual growth rate of nearly 15%. That's not easy to pull off, but it is certainly possible. The

Despite lingering economic issues, the broader stock market has recovered this year. But some companies are failing to keep up for a variety of reasons. Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ:

Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year. And although its stock is still up by 20% in the trailing-12-month period, the company's shares recently

AbbVie (NYSE: ABBV) is a leading pharmaceutical company that rewards its shareholders with a generous dividend policy. The company has a history of increasing its dividends for more than 50 years in

Novocure (NASDAQ: NVCR) shares dropped after publishing the results of an important clinical trial. The headlines looked positive at first glance, but the study raised concerns that lung cancer

Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the

If you're looking to invest in the stock market this summer, there are many great options out there to consider. Whether you're after dividends, growth, or simply long-term stability, there are

Cathie Wood's Ark Investment Management has deemed CRISPR/Cas 9 genome editing as "biotech's breakthrough of the century." Back in 2018, Ark identified this gene-editing tool as a potential $2

There are many ways to determine whether a stock is cheap, but one way of doing so is determining whether there is substantial upside potential for the company. And while the market often bids up

Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong. But these companies are all preparing for what's

Regeneron Pharmaceuticals' (NASDAQ: REGN) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for

A new month is here. And with it comes a new opportunity to invest in spectacular dividend stocks.

Three Motley Fool contributors think they know some great candidates to buy in July. Here's why

Drug companies Merck (NYSE: MRK) and AbbVie (NYSE: ABBV) have been two of the best pharmaceutical investments, easily delivering better total returns than the S&P 500 average over the past three

Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.

However

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults